Pherin Pharmaceuticals

Los Altos, United States Founded: 1991 • Age: 35 yrs Acquired By VistaGen
Intranasal pherines for anxiety and depression treatments are developed.

About Pherin Pharmaceuticals

Pherin Pharmaceuticals is a Healthcare company based in Los Altos (United States) founded in 1991, and was acquired by VistaGen in December 2022. Intranasal pherines for anxiety and depression treatments are developed. Its chief executive, as recorded, is Kevin McCarthy. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Psychiatric. Its competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance; 2 of its 3 listed competitors have raised funding.

Company details

Pherin Pharmaceuticals is a clinical stage specialty drug development company. It develops intranasal spray delivery in ultra low (nanogram) dose. It works exclusively with a set of proprietary compounds called pherines for the acute and PRN treatment of neuropsychiatric and neuroendocrine conditions. Pherines act by binding to nasal receptors and initiating neural impulses that are transmitted by specific neural circuits that directly and rapidly affect brain function. Their pipeline consists of four lead compounds: Aloradine IN for acute treatment of Social Anxiety Disorder (currently in Phase III); PH10 nasal spray for acute treatment of Depression (currently in Phase II); Salubrin HF NS, for acute management of Menopausal Hot Flashes and other symptoms of menopause (also in Phase II); and PH15 nasal spray for Cognitive Improvement (in Phase I trials).

  • Headquarters Los Altos, United States
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website pherin.com
  • Acquired by VistaGen (Dec 2022)
Operational Areas
Key Metrics
  • Latest Funding Round
    $1.5M (USD), Unspecified

    Jul 1999

  • Investors
    VistaGen

    & 1 more

  • Acquired by
    VistaGen

    (Dec 2022)

Funding Insights of Pherin Pharmaceuticals

  • Total Rounds 1
  • Last Round Unspecified β€” $1.5M
  • First Round $1.5M

    (Jul 1999)

  • Investors Count 1

All 1 funding rounds of Pherin Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 1999$1.5MUnspecified––
Valuation history

2 investors in total: 2 institutional.

Investors in Pherin Pharmaceuticals

Pherin Pharmaceuticals has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include VistaGen and Johnson & Johnson Innovation – JJDC.

All
Venture Fund
InvestorDescriptionFounded YearDomainLocation
Venture capital firm backed by Johnson & Johnson
jnjinnovation.com/jjdcCambridge, United States
Small molecules are developed for CNS disease treatments.
1998vistagen.comFrancisco, United States
Premium access

Investor details for Pherin Pharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Pherin Pharmaceuticals

1 people are tracked at Pherin Pharmaceuticals (1 in leadership).

NameRoleGroup
Kevin McCarthy
CEOLeadership
Premium access

Complete people profiles for Pherin Pharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Pherin Pharmaceuticals

3 dated milestones of Pherin Pharmaceuticals across 31 years, from founding to its latest funding, stage changes and deals.

  1. Founded Pherin Pharmaceuticals is founded.
  2. Funding First funding round of $1.5M.
  3. Exit Acquired by VistaGen.

Competitors of Pherin Pharmaceuticals

Pherin Pharmaceuticals has 3 listed competitors in our database, 2 of them funded. They include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
altoneuroscience.com2019San Francisco, United States$144.72M34
AI-driven drug discovery platform for neurological diseases based on patients biomarkers
supernus.com2005Rockville, United States652
Specialty pharmaceutical products for CNS diseases are developed and commercialized.
neurovance.com2011Cambridge, United States$53.03M7
Neurochemical modulators for ADHD treatment are developed by Neurovance.
Premium access

Detailed competitors of Pherin Pharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Pherin Pharmaceuticals

Websites that share an audience with Pherin Pharmaceuticals (pherin.com).

Similar websites

Websites whose visitors overlap most with Pherin Pharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
thresholdpharm.com
100%
View details
sucampo.com
98%
View details
aqxpharma.com
98%
3K#6,768,702View details
noven.com
98%
7.2K#3,107,578View details
pacira.com
98%
39.1K#1,306,031View details
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’β€’.comβ€’β€’%β€’.β€’M#‒‒‒‒‒–
Premium access

All 8 similar websites and full traffic analytics for Pherin Pharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 8 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Neurology

3 companies that operate in the same segment as Pherin Pharmaceuticals (Neurology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
2013San Francisco, California, United StatesUSD 214.78 MUSD 21.05 M211
Developer of therapeutics for psychiatric and neurologic diseases
2002New York, New York, United StatesUSD 80.87 MUSD 250.31 M600
Biologics platform developed for intracellular delivery in rare diseases.
2016Boston, Massachusetts, United StatesUSD 175.25 MUSD 25.42 M183
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Pherin Pharmaceuticals

Premium access

Complete news archive for Pherin Pharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Pherin Pharmaceuticals

Pherin Pharmaceuticals was founded in 1991 and raised its 1st funding round 8 years after it was founded.

Pherin Pharmaceuticals is headquartered in Los Altos, United States. It is registered at Los Altos, California, United States.

Kevin McCarthy is the CEO of Pherin Pharmaceuticals, as recorded in our data.

Pherin Pharmaceuticals is a clinical stage specialty drug development company. It develops intranasal spray delivery in ultra low (nanogram) dose. It works exclusively with a set of proprietary compounds called pherines for the acute and PRN treatment of neuropsychiatric and neuroendocrine conditions. Pherines act by binding to nasal receptors and initiating neural impulses that are transmitted by specific neural circuits that directly and rapidly affect brain function. Their pipeline consists of four lead compounds: Aloradine IN for acute treatment of Social Anxiety Disorder (currently in Phase III); PH10 nasal spray for acute treatment of Depression (currently in Phase II); Salubrin HF NS, for acute management of Menopausal Hot Flashes and other symptoms of menopause (also in Phase II); and PH15 nasal spray for Cognitive Improvement (in Phase I trials).

Pherin Pharmaceuticals's top competitors include Alto Neuroscience, Supernus Pharmaceuticals and Neurovance.

Pherin Pharmaceuticals has 2 investors. Key investors include VistaGen, and Johnson & Johnson Innovation – JJDC.

Yes. Pherin Pharmaceuticals was acquired by VistaGen in December 2022.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available